1. Search Result
Search Result
Results for "

Fc receptor

" in MedChemExpress (MCE) Product Catalog:

87

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

68

Inhibitory Antibodies

2

Natural
Products

610

Recombinant Proteins

4

Isotope-Labeled Compounds

14

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9977
    Amivantamab
    3 Publications Verification

    JNJ-61186372

    EGFR Inflammation/Immunology Cancer
    Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
    Amivantamab
  • HY-P99930
    Efruxifermin
    2 Publications Verification

    AKR-001; AMG-876

    FGFR Metabolic Disease
    Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
    Efruxifermin
  • HY-P9950
    Omalizumab
    1 Publications Verification

    Olizumab; rhuMab-E25; IGE25; RG-3648

    Interleukin Related Inflammation/Immunology Cancer
    Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research . The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
    Omalizumab
  • HY-P99590
    Sotatercept
    2 Publications Verification

    ACE-011; MK-7962

    TGF-β Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
    Sotatercept
  • HY-B0723
    Ospemifene
    2 Publications Verification

    Fc-1271a

    Estrogen Receptor/ERR Caspase Neurological Disease Endocrinology Cancer
    Ospemifene (FC-1271a) is an orally active and non-estrogenic selective estrogen receptor modulator (SERM) with Ki values of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene inhibits caspase-3 activity. Ospemifene inhibits neuronal degeneration, prevents bone loss, and increases vaginal weight and vaginal epithelial height. Ospemifene has anticancer activity against breast cancer .
    Ospemifene
  • HY-147305

    ARGX-113

    Fc Receptor (FcR) Inflammation/Immunology
    Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research .
    Efgartigimod alfa
  • HY-13690
    Mitotane
    5 Publications Verification

    2,4′-DDD; o,p'-DDD

    Apoptosis Cancer
    Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions .
    Mitotane
  • HY-P9954

    CD3 Cancer
    Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
    Catumaxomab
  • HY-P9979
    Rozanolixizumab
    1 Publications Verification

    UCB7665

    TNF Receptor Inflammation/Immunology
    Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
    Rozanolixizumab
  • HY-P99222

    MGA-031; PRV-031

    CD3 Metabolic Disease
    Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
    Teplizumab
  • HY-P990715

    INBRX-109

    TNF Receptor Cancer
    Ozekibart (INBRX-109) is a DR5 agonist and antitumor agent with a human DR5 IC50 of 0.17 nmol/L and human DR5 Ka of 0.11 nmol/L. Ozekibart can be used for the research of unresectable/metastatic chondrosarcoma .
    Ozekibart
  • HY-P991155

    JNJ-79635322; JNJ-5322

    CD3 TNF Receptor Cancer
    Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
    Ramantamig
  • HY-P99761

    XmAb5871

    CD19 Apoptosis Inflammation/Immunology
    Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .
    Obexelimab
  • HY-P99300
    Ligelizumab
    1 Publications Verification

    QGE 031; Anti-IGHE Recombinant Antibody

    Fc Receptor (FcR) Inflammation/Immunology
    Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .
    Ligelizumab
  • HY-NP006
    Protein A
    1 Publications Verification

    SPA

    Endogenous Metabolite Apoptosis Inflammation/Immunology
    Protein A (SPA) is an immunoglobulin (Ig)-binding protein that exists on the bacterial surface and can be freely secreted into the extracellular environment. Protein A blocks opsonophagocytosis and induces B cell apoptosis in vitro by binding to the Fc region of antibodies and the Fab region of B cell receptors. Protein A can form toxic immune complexes with IgG, thereby inducing leukocyte necrosis. Protein A contributes to the virulence expression of Staphylococcus aureus. Protein A triggers allergic reactions in IgG-pretreated mouse models. Protein A can be used in studies related to immune system diseases .
    Protein A
  • HY-15322
    PRT062607
    4 Publications Verification

    P505-15; PRT-2607; BIIB-057

    Syk Apoptosis Caspase Inflammation/Immunology Cancer
    PRT062607 (P505-15; PRT-2607) is an orally active ATP-competitive Syk inhibitor with an IC50 value of 1 nM, and exhibits at least 80-fold selectivity over other kinases. PRT062607 blocks B cell antigen receptor-mediated activation, Fcε receptor 1-mediated basophil degranulation and microglial phagocytosis, and induces caspase-dependent apoptosis and microglial death. PRT062607 inhibits tumor growth and peripheral nerve injury-induced mechanical allodynia, and prevents neuronal loss. PRT062607 can be used in research related to rheumatoid arthritis, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, neurodegenerative diseases and neuropathic pain .
    PRT062607
  • HY-P99446

    TACI-Ig; TACI-Fc 5

    TNF Receptor Inflammation/Immunology
    Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .
    Atacicept
  • HY-P99934
    Eftozanermin alfa
    1 Publications Verification

    ABBV-621

    Apoptosis Caspase TNF Receptor Cancer
    Eftozanermin alfa (ABBV-621) is a tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa is a fusion protein consisting of a mutant immunoglobulin G1-Fc linked to 2 single-chain trimers of TRAIL. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors (DR4 receptor and DR5 receptor) with Kds of 780 nM and 635 nM. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .
    Eftozanermin alfa
  • HY-P99489

    ABBV 181; PR 1648817

    PD-1/PD-L1 Inflammation/Immunology Cancer
    Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
    Budigalimab
  • HY-P99332

    Anti-Human CD3E Recombinant Antibody; HuM291

    Apoptosis Inflammation/Immunology Cancer
    Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
    Visilizumab
  • HY-109010
    Poseltinib
    2 Publications Verification

    HM71224; LY3337641

    Btk BMX Kinase Toll-like Receptor (TLR) Metabolic Disease
    Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Bruton tyrosine kinase (BTK) inhibitor. With an IC50 of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR). Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis .
    Poseltinib
  • HY-P99665

    LY-3209590

    Insulin Receptor Metabolic Disease
    Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
    Insulin efsitora alfa
  • HY-P99315

    BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8

    TNF Receptor Inflammation/Immunology
    Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Ruplizumab
  • HY-P99804
    Clesrovimab
    3 Publications Verification

    MK1654

    RSV Infection
    Clesrovimab (MK1654) is a humanized IgG1 monoclonal antibody targeting the respiratory syncytial virus (RSV) protein F. Clesrovimab binds to pre-fusion and post-fusion forms of RSV-A fusion protein with high affinity, with corresponding KD values of 71 pM and 480 pM, respectively. Clesrovimab is applicable for the research of RSV infection .
    Clesrovimab
  • HY-P99667
    Ipafricept
    4 Publications Verification

    OMP-54F28; FZD8-Fc

    Wnt Cancer
    Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
    Ipafricept
  • HY-P99546

    2xCon4C; AMG 386

    Tie Cardiovascular Disease Cancer
    Trebananib (2xCon4C) is an Fc fusion peptibody. Trebananib exerts its effects by blocking the binding of angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) to the TIE2 receptor. Trebananib has anti-angiogenic and anti-tumor activities .
    Trebananib
  • HY-P99470

    GEN1029

    TNF Receptor Apoptosis Cancer
    Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
    Benufutamab
  • HY-P99008
    Atibuclimab
    2 Publications Verification

    IC14

    Toll-like Receptor (TLR) Infection Neurological Disease Inflammation/Immunology
    Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
    Atibuclimab
  • HY-P99661
    Inbakicept
    2 Publications Verification

    Interleukin Related Cancer
    Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
    Inbakicept
  • HY-P99529

    BAX1810; TAK-752; SM101

    Fc Receptor (FcR) Inflammation/Immunology
    Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE) .

    Valziflocept
  • HY-P991055

    RG-6234; RO-7425781

    CD3 Inflammation/Immunology
    Forimtamig (RG-6324) is a GPRC5DxCD3 T-cell-engaging bispecific antibody. Forimtamig has a 2 + 1 format, comprising two high-affinity GPRC5D binding moieties and one CD3 binder. Forimtamig further features a P329G LALA mutated Fc domain that inhibits Fcγ receptor and C1q binding, yet retains binding to the neonatal Fc receptor. The isotype control for Forimtamig can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    Forimtamig
  • HY-P990256

    CTLA-4 Inflammation/Immunology Cancer
    Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) is a mouse-derived IgG2a κ type antibody inhibitor targeting to mouse CTLA-4/CD152. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) can be used for the researches of cancer and immunology, such as colon .
    Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9)
  • HY-P9977A

    EGFR Cancer
    Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
    Amivantamab (FUT8-KO)
  • HY-P99125

    Fc Receptor (FcR) Cardiovascular Disease Inflammation/Immunology
    Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders .
    Anti-Mouse CD16/CD32 Antibody (2.4G2)
  • HY-139690
    CCG258747
    1 Publications Verification

    Opioid Receptor G Protein-coupled Receptor Kinase (GRK) Mas-related G-protein-coupled Receptor (MRGPR) Cardiovascular Disease Inflammation/Immunology
    CCG258747 is a selective GRK2 inhibitor (IC50 = 18 nM) with high selectivity over GRK1, GRK5, PKA, and ROCK1 (518, 83, > 5500, and > 550-fold, respectively). CCG258747 also blocks the internalization of the µ-opioid receptor (MOR). CCG258747 attenuates IgE mediated anaphylaxis by inhibiting GRK2 and FcεRI signaling pathway but activates mast cells via MRGPRX2 and MRGPRB2. CCG258747 can be used to study diseases related to overexpression of GRK2 (such as heart failure, opioid tolerance) .
    CCG258747
  • HY-P990172

    PD-1/PD-L1 Cancer
    Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG1. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) can be used for the research of cancer.
    Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2)
  • HY-P990171

    PD-1/PD-L1 Cancer
    Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a recombinant chimeric version of the original 10F.9G2 antibody (HY-P99145). The variable domain sequences are identical to the original 10F.9G2 but the constant region sequences have been switched from rat IgG2b to mouse IgG2a. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) can be used for the research of cancer.
    Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)
  • HY-P99830

    KH902

    VEGFR TNF Receptor Interleukin Related Cardiovascular Disease Inflammation/Immunology Cancer
    Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC50 = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (Kd = 0.5 pM), VEGF-B (Kd = 8 pM), VEGF-C, and PlGF (Kd = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .
    Conbercept
  • HY-P99381
    XmAb 5592
    1 Publications Verification

    Transmembrane Glycoprotein Cancer
    XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .
    XmAb 5592
  • HY-P991086

    PRV-3279

    Fc Receptor (FcR) Inflammation/Immunology
    MGD010 (PRV-3279) is a bispecific antibody targeting CD32B (FcγRIIb) and CD79B. MGD010 transmits negative signals by simultaneously co-linking CD32B (FcγRIIb) with CD79B, a component of the B-cell receptor (BCR), thereby inhibiting activated B cells. MGD010 can be used in research related to autoimmune diseases .
    MGD010
  • HY-P990067

    ATOR-1017

    TNF Receptor Cancer
    Evunzekibart (ATOR-1017) is an Fcreceptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.
    Evunzekibart
  • HY-P990291

    Fc Receptor (FcR) Inflammation/Immunology Cancer
    Anti-Mouse CD16.2 Antibody (9E9) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD16.2. Anti-Mouse CD16.2 Antibody (9E9) reacts with mouse CD16.2, also known as FcγRIV (Fc receptor, IgG, low affinity IV). Anti-Mouse CD16.2 Antibody (9E9) inhibits cellular CD16.2 expression and signaling and blocks FcγRIV. Anti-Mouse CD16.2 Antibody (9E9) can be used for the researches of cancer, inflammation and immunology, such as CT26 tumor and lung inflammation .
    Anti-Mouse CD16.2 Antibody (9E9)
  • HY-N16039

    β-glucuronidase Inflammation/Immunology
    TAN-1030A is an indolocarbazole alkaloid with macrophage-activating properties. TAN-1030A induces spreading of a murine macrophage cell line, Mm 1, and augmentes the phagocytic activity, Fc gamma receptor expression and β-glucuronidase activity of murine macrophage cell lines, Mm 1 and J774A.1. TAN-1030A can activate macrophage functions in mice .
    TAN-1030A
  • HY-P991214

    EMD 273066; huKS-IL2

    Interleukin Related Cancer
    Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine. Tucotuzumab celmoleukin consists of the following components: an IgG1 monoclonal antibody targeting human EpCAM antigen, and two molecules of IL2. Tucotuzumab celmoleukin binds to EpCAM. Tucotuzumab celmoleukin exerts anti-tumor effects on colon adenocarcinoma in synergy with radiofrequency ablation. Tucotuzumab celmoleukin can be used in research related to colon adenocarcinoma and colon cancer .
    Tucotuzumab celmoleukin
  • HY-P990863

    Fc Receptor (FcR) Infection Inflammation/Immunology
    Anti-CD32/FcγRIIA Antibody (IV.3) is a kind of mouse IgG2b chimeric antibody inhibitor, targeting to human CD32/FcγRIIA. Anti-CD32/FcγRIIA Antibody (IV.3) can block Fc receptor IIA. Anti-CD32/FcγRIIA Antibody (IV.3) can be used for the researches of inflammation and infection, such as arthritis and E. coli infection .
    Anti-CD32/FcγRIIA Antibody (IV.3)
  • HY-W078239

    Ephrin Receptor Cancer
    EPHA4 antagonist-1 (Compound 2) is an EphA4 receptor antagonist. EPHA4 antagonist-1 is also an EphA2 receptor antagonist. EPHA4 antagonist-1 inhibits ephrin-A5 AP binding to EphA4 Fc receptor, with an IC50 of 10 μM .
    EPHA4 antagonist-1
  • HY-P990269

    TNF Receptor Inflammation/Immunology Cancer
    Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG2a. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.
    Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)
  • HY-P99487

    BR 3Fc

    ADC Antibody Inflammation/Immunology
    Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) .
    Briobacept
  • HY-P990720

    KER-050

    TGF-beta/Smad Inflammation/Immunology
    Elritercept (KER-050) is a recombinant fusion protein comprising a modified activin receptor type IIA extracellular domain fused to a human IgG1 Fc. Elritercept inhibits activin A and other select TGF-β superfamily ligands .
    Elritercept
  • HY-P991074

    Fc Receptor (FcR) Inflammation/Immunology
    GMA-161 is a humanized IgG1 antibody that targets Fcγ receptor III (CD16). GMA-161 has the potential for the study of autoimmune disorders. The isotype control for GMA-161 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
    GMA-161

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: